ArticleTuberculosis research and treatment2012
Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.
Article in Tuberculosis research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- The role of IgA and IgG in Mycobacterium tuberculosis infection: a cross-sectional study in Ethiopia.Clinical and experimental immunology · 2026Article
- The Role and Potential Application of IL-12 in the Immune Regulation of Tuberculosis.International journal of molecular sciences · 2025Review
- Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.Scientific reports · 2025Article
- Editorial: Tuberculosis and humoral immunity.Frontiers in immunology · 2025Article
- Intranasal BCG vaccination induces systemic and pulmonary mucosal immune responses against tuberculosis in a goat model.Frontiers in immunology · 2025Article
- Clarification of a unique mucosal vaccination route for improved systemic and mucosal immune response in broiler.Heliyon · 2024Article
- Review
- Target Identification in Anti-Tuberculosis Drug Discovery.International journal of molecular sciences · 2023Review
- Generating enhanced mucosal immunity againstFrontiers in immunology · 2023Article
- Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis.Cell reports · 2022Article
- BCG vaccination strategies against tuberculosis: updates and perspectives.Human vaccines & immunotherapeutics · 2021Review
- Characterization of local and circulating bovine γδ T cell responses to respiratory BCG vaccination.Scientific reports · 2019Article
- Mycobacterium tuberculosis Rv3463 induces mycobactericidal activity in macrophages by enhancing phagolysosomal fusion and exhibits therapeutic potential.Scientific reports · 2019Article
- The Humoral Immune Response to BCG Vaccination.Frontiers in immunology · 2019Review
- Epithelial Cells Attenuate Toll-Like Receptor-Mediated Inflammatory Responses in Monocyte-Derived Macrophage-Like Cells toMediators of inflammation · 2018Article
- Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure toF1000Research · 2018Review
- Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa.Journal of immunology research · 2018Article
- Cytokine regulation of lung Th17 response to airway immunization using LPS adjuvant.Mucosal immunology · 2017Article
- Alveolar Epithelial Cells in Mycobacterium tuberculosis Infection: Active Players or Innocent Bystanders?Journal of innate immunity · 2016Review
- Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination.Microbes and infection · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is one of the world's leading infectious causes of morbidity and mortality. As a mucosal-transmitted pathogen, Mtb infects humans and animals mainly through the mucosal tissue of the respiratory tract. Apart from providing a physical barrier against the invasion of pathogen, the major function of the respiratory mucosa may be to serve as the inductive sites to initiate mucosal immune responses and sequentially provide the first line of defense for the host to defend against this pathogen. A large body of studies in the animals and humans have demonstrated that the mucosal immune system, rather than the systemic immune system, plays fundamental roles in the host's defense against Mtb infection. Therefore, the development of new vaccines and novel delivery routes capable of directly inducing respiratory mucosal immunity is emphasized for achieving enhanced protection from Mtb infection. In this paper, we outline the current state of knowledge regarding the mucosal immunity against Mtb infection, including the development of TB vaccines, and respiratory delivery routes to enhance mucosal immunity are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.